Adicet Bio (ACET) Expected to Announce Quarterly Earnings on Thursday

Adicet Bio (NASDAQ:ACET) is expected to post its Q4 2025 results before the market opens on Thursday, March 5th. Analysts expect Adicet Bio to post earnings of ($3.23) per share for the quarter. Individuals are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Friday, March 13, 2026 at 5:00 PM ET.

Adicet Bio Price Performance

ACET opened at $7.02 on Wednesday. The company has a fifty day moving average price of $7.77 and a two-hundred day moving average price of $10.27. The firm has a market capitalization of $67.25 million, a PE ratio of -0.35 and a beta of 1.56. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.62 and a current ratio of 5.62. Adicet Bio has a 52 week low of $6.41 and a 52 week high of $17.44.

Institutional Investors Weigh In On Adicet Bio

A number of institutional investors have recently modified their holdings of the business. Franklin Resources Inc. bought a new stake in shares of Adicet Bio in the fourth quarter valued at approximately $5,276,000. Two Sigma Investments LP lifted its position in shares of Adicet Bio by 66.6% during the 3rd quarter. Two Sigma Investments LP now owns 854,568 shares of the company’s stock valued at $692,000 after acquiring an additional 341,761 shares during the period. Adage Capital Partners GP L.L.C. bought a new stake in shares of Adicet Bio during the 4th quarter valued at $2,310,000. Prosight Management LP acquired a new stake in shares of Adicet Bio during the 4th quarter worth $2,107,000. Finally, ADAR1 Capital Management LLC bought a new position in shares of Adicet Bio in the fourth quarter worth $1,083,000. Institutional investors own 83.89% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently issued reports on ACET. Weiss Ratings reissued a “sell (d-)” rating on shares of Adicet Bio in a research note on Tuesday, January 27th. Canaccord Genuity Group set a $18.00 price target on shares of Adicet Bio and gave the stock a “buy” rating in a research report on Tuesday, January 6th. HC Wainwright restated a “buy” rating and issued a $50.00 price objective (up from $9.00) on shares of Adicet Bio in a report on Wednesday, January 21st. Wedbush reaffirmed an “outperform” rating and issued a $80.00 target price on shares of Adicet Bio in a research report on Thursday, November 6th. Finally, Citigroup reiterated a “market perform” rating on shares of Adicet Bio in a report on Wednesday, November 19th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Adicet Bio currently has an average rating of “Moderate Buy” and a consensus target price of $69.00.

Adicet Bio Company Profile

Adicet Bio, Inc (NASDAQ: ACET) is a clinical‐stage biotechnology company specializing in the development of off‐the‐shelf, allogeneic gamma delta (γδ) T cell therapies for oncology and autoimmune disorders. The company’s proprietary platform enables the genetic engineering of γδ T cells with chimeric antigen receptors (CARs) and other molecular modifications to enhance tumor targeting, expansion, and persistence. By leveraging the innate tumor-recognition properties of γδ T cells, Adicet seeks to overcome the manufacturing and safety challenges associated with autologous cell therapies.

Adicet’s lead product candidate, ADI-001, is a CAR‐engineered allogeneic γδ T cell therapy directed against CD20 for the treatment of relapsed or refractory B-cell malignancies.